DECR2

Summary

DECR2 (2,4-dienoyl-CoA reductase 2, HGNC:2754) is a protein-coding gene on chromosome 16p13.3, encoding Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] (Q9NUI1). Auxiliary enzyme of beta-oxidation.

Enables 2,4-dienoyl-CoA reductase (NADPH) activity and trans-2-enoyl-CoA reductase (NADPH) activity. Involved in unsaturated fatty acid biosynthetic process. Predicted to be located in cytosol and peroxisomal membrane. Predicted to be active in peroxisome.

Source: NCBI Gene 26063 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 100 total
• Druggable target: yes
• MANE Select transcript: NM_020664

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2754
Approved symbol	DECR2
Name	2,4-dienoyl-CoA reductase 2
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	PDCR, SDR17C1
Ensembl gene	ENSG00000242612
Ensembl biotype	protein_coding
OMIM	615839
Entrez	26063

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 18 protein_coding, 6 nonsense_mediated_decay, 3 retained_intron, 3 protein_coding_CDS_not_defined

ENST00000219481, ENST00000424398, ENST00000429116, ENST00000437024, ENST00000439661, ENST00000445291, ENST00000461749, ENST00000461802, ENST00000461947, ENST00000465166, ENST00000469922, ENST00000627716, ENST00000631605, ENST00000632744, ENST00000633025, ENST00000633348, ENST00000633923, ENST00000876953, ENST00000876954, ENST00000876955, ENST00000876956, ENST00000876957, ENST00000876958, ENST00000876959, ENST00000876960, ENST00000876961, ENST00000876962, ENST00000931574, ENST00000949770, ENST00000949771

RefSeq mRNA: 1 — MANE Select: NM_020664 NM_020664

CCDS: CCDS10409

Canonical transcript exons

ENST00000219481 — 9 exons

Exon	Start	End
ENSE00003496745	410691	410784
ENSE00003554540	406346	406397
ENSE00003558181	410243	410367
ENSE00003633106	404956	405024
ENSE00003640577	407425	407560
ENSE00003643647	411361	411578
ENSE00003780221	401885	402043
ENSE00003790014	410972	411076
ENSE00003846318	411890	412482

Expression profiles

Bgee: expression breadth ubiquitous, 137 present calls, max score 98.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.4641 / max 177.9587, expressed in 1754 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
151913	5.7786	1722
151914	2.6396	1405
151916	0.0158	5
151915	0.0157	7
151917	0.0144	5

Top tissues by expression

137 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	98.32	gold quality
liver	UBERON:0002107	96.67	gold quality
right adrenal gland cortex	UBERON:0035827	94.34	gold quality
mucosa of transverse colon	UBERON:0004991	94.31	gold quality
left adrenal gland cortex	UBERON:0035825	94.17	gold quality
right adrenal gland	UBERON:0001233	93.96	gold quality
duodenum	UBERON:0002114	93.77	gold quality
left adrenal gland	UBERON:0001234	93.60	gold quality
transverse colon	UBERON:0001157	92.17	gold quality
cortex of kidney	UBERON:0001225	92.14	gold quality
adult mammalian kidney	UBERON:0000082	92.05	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.02	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.42	gold quality
apex of heart	UBERON:0002098	91.19	gold quality
body of pancreas	UBERON:0001150	91.17	gold quality
adrenal gland	UBERON:0002369	90.90	gold quality
metanephros cortex	UBERON:0010533	90.89	gold quality
gastrocnemius	UBERON:0001388	90.83	gold quality
small intestine	UBERON:0002108	90.76	gold quality
muscle of leg	UBERON:0001383	90.33	gold quality
colon	UBERON:0001155	89.46	gold quality
kidney	UBERON:0002113	89.36	gold quality
body of stomach	UBERON:0001161	89.35	gold quality
intestine	UBERON:0000160	89.28	gold quality
fundus of stomach	UBERON:0001160	89.09	gold quality
muscle layer of sigmoid colon	UBERON:0035805	88.05	gold quality
left uterine tube	UBERON:0001303	87.67	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.67	gold quality
cerebellar hemisphere	UBERON:0002245	87.61	gold quality
prostate gland	UBERON:0002367	87.60	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting DECR2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-451B	99.55	68.28	1380
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-3925-5P	99.21	67.90	1466
HSA-MIR-491-3P	98.88	68.86	1224
HSA-MIR-6829-5P	98.86	65.12	1480
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-1227-5P	98.65	65.32	1549
HSA-MIR-6868-3P	98.63	69.64	2259
HSA-MIR-6765-3P	97.83	64.59	1165
HSA-MIR-1226-3P	97.51	66.32	1063
HSA-MIR-3157-5P	97.41	67.61	998

Literature-anchored findings (GeneRIF, showing 1)

• Peroxisomal beta-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer. (PMID:38216720)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	decr2	ENSDARG00000045257
mus_musculus	Decr2	ENSMUSG00000036775
rattus_norvegicus	Decr2	ENSRNOG00000088984

Paralogs (1): DECR1 (ENSG00000104325)

Protein

Protein identifiers

Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] — Q9NUI1 (reviewed: Q9NUI1)

Alternative names: 2,4-dienoyl-CoA reductase 2, Short chain dehydrogenase/reductase family 17C member 1

All UniProt accessions (7): A0A0J9YWI0, A0A0J9YXZ6, A0A0J9YY83, Q9NUI1, G3V0I9, H7C078, Q4VXZ8

UniProt curated annotations — full annotation on UniProt →

Function. Auxiliary enzyme of beta-oxidation. Participates in the degradation of unsaturated fatty enoyl-CoA esters having double bonds in both even- and odd-numbered positions in peroxisome. Catalyzes the NADP-dependent reduction of 2,4-dienoyl-CoA to yield trans-3-enoyl-CoA. Has activity towards short and medium chain 2,4-dienoyl-CoAs, but also towards 2,4,7,10,13,16,19-docosaheptaenoyl-CoA, suggesting that it does not constitute a rate limiting step in the peroxisomal degradation of docosahexaenoic acid.

Subunit / interactions. Monomer, dimer and oligomer.

Subcellular location. Peroxisome.

Similarity. Belongs to the short-chain dehydrogenases/reductases (SDR) family. 2,4-dienoyl-CoA reductase subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NUI1-1	1	yes
Q9NUI1-2	2
Q9NUI1-3	3

RefSeq proteins (1): NP_065715* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002347	SDR_fam	Family
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily
IPR045017	DECR2-like	Family
IPR057326	KR_dom	Domain

Pfam: PF13561

Enzyme classification (BRENDA):

• EC 1.3.1.124 — 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] (BRENDA: 7 organisms, 32 substrates, 3 inhibitors, 26 Km, 1 kcat entries)
• EC 1.3.1.34 — 2,4-dienoyl-CoA reductase [(2E)-enoyl-CoA-producing] (BRENDA: 7 organisms, 19 substrates, 4 inhibitors, 17 Km, 7 kcat entries)

Substrate kinetics (BRENDA)

19 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
NADPH	0.0025–0.215	8
NADPH	0.0004–0.0605	8
TRANS-TRANS-2,4-HEXADIENOYL-COA	0.0045–0.154	5
(2E,4E)-2,4-DECADIENOYL-COA	0.006–0.0154	3
(2E,4E)-2,4-HEXADIENOYL-COA	0.0265–0.059	2
2,4,7,10,13,16,19-DOCOSAHEPTAENOYL-COA	0.102–0.155	2
2-TRANS,4-TRANS-HEXADIENOYL-COA	0.0005–0.108	2
(2E,4E)-2,4-OCTADIENOYL-COA	0.0158	1
2,4-DECADIENOYL-COA	0.006	1
2-FLUORO-TRANS-TRANS-2,4-OCTADIENOYL-COA	0.0065	1
5-METHYL-TRANS-TRANS-2,4-HEXADIENOYL-COA	0.016	1
(2E,4E)-2,4-DECADIENOYL-COA	0.0127	1
(2E,4E)-2,4-HEXADIENOYL-COA	0.0716	1
2,4,7,10,13,16,19-DOCOSAHEPTAENOYL-COA	0.102	1

Catalyzed reactions (Rhea), 3 shown:

• (2E,4Z,7Z,10Z,13Z,16Z,19Z)-docosaheptaenoyl-CoA + NADPH + H(+) = (3E,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-CoA + NADP(+) (RHEA:44920)
• a (2E,4E)-dienoyl-CoA + NADPH + H(+) = a 4,5-saturated-(3E)-enoyl-CoA + NADP(+) (RHEA:45912)
• a (2E,4Z)-dienoyl-CoA + NADPH + H(+) = a 4,5-saturated-(3E)-enoyl-CoA + NADP(+) (RHEA:61892)

UniProt features (52 total): helix 15, binding site 10, strand 9, modified residue 4, splice variant 4, mutagenesis site 4, turn 3, initiator methionine 1, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
4FC7	X-RAY DIFFRACTION	1.84
4FC6	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NUI1-F1	95.77	0.92

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (10): 182; 208–214; 219; 35–40; 60–64; 60; 86; 88; 118; 126–128

Post-translational modifications (4): 2, 151, 287, 291

Mutagenesis-validated functional residues (4):

Position	Phenotype
86	reduces enzyme activity by 98%.
137	reduces enzyme activity by 97%.
186	reduces enzyme activity by about 95%.
268	reduces enzyme activity by 97%.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-390247	Beta-oxidation of very long chain fatty acids
R-HSA-9033241	Peroxisomal protein import

MSigDB gene sets: 111 (showing top): GOBP_LIPID_MODIFICATION, GOBP_FATTY_ACID_CATABOLIC_PROCESS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOMF_GTPASE_BINDING, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_FATTY_ACID_BETA_OXIDATION_USING_ACYL_COA_OXIDASE, GOBP_ORGANIC_ACID_CATABOLIC_PROCESS, GOBP_FATTY_ACID_BIOSYNTHETIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS

GO Biological Process (5): fatty acid metabolic process (GO:0006631), unsaturated fatty acid biosynthetic process (GO:0006636), fatty acid beta-oxidation using acyl-CoA oxidase (GO:0033540), lipid metabolic process (GO:0006629), fatty acid catabolic process (GO:0009062)

GO Molecular Function (6): 2,4-dienoyl-CoA reductase (NADPH) activity (GO:0008670), trans-2-enoyl-CoA reductase (NADPH) activity (GO:0019166), protein-containing complex binding (GO:0044877), GTPase binding (GO:0051020), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (3): peroxisome (GO:0005777), peroxisomal membrane (GO:0005778), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Peroxisomal lipid metabolism	1
Protein localization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor	2
binding	2
lipid metabolic process	1
monocarboxylic acid metabolic process	1
fatty acid biosynthetic process	1
unsaturated fatty acid metabolic process	1
fatty acid beta-oxidation	1
primary metabolic process	1
fatty acid metabolic process	1
lipid catabolic process	1
monocarboxylic acid catabolic process	1
enzyme binding	1
catalytic activity	1
microbody	1
peroxisome	1
microbody membrane	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

3719 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DECR2	ACOX1	Q15067	631
DECR2	HSD17B4	P51659	578
DECR2	ECI2	O75521	537
DECR2	PRR35	P0CG20	522
DECR2	ZNF563	Q8TA94	519
DECR2	EHHADH	Q08426	518
DECR2	ECI1	P42126	496
DECR2	KBTBD12	Q3ZCT8	492
DECR2	ACAA1	P09110	491
DECR2	RRP36	Q96EU6	464
DECR2	RAB11FIP3	O75154	460
DECR2	TOGARAM1	Q9Y4F4	450
DECR2	ACOT8	O14734	440
DECR2	IHO1	Q8IYA8	437
DECR2	KCNG3	Q8TAE7	431

IntAct

63 interactions, top by confidence:

A	B	Type	Score
NHERF2	PODXL	psi-mi:“MI:0914”(association)	0.770
OSGIN1	DECR2	psi-mi:“MI:0915”(physical association)	0.560
VPS26C	DECR2	psi-mi:“MI:0915”(physical association)	0.560
DECR2	C14orf119	psi-mi:“MI:0915”(physical association)	0.560
USP11	DECR2	psi-mi:“MI:0915”(physical association)	0.560
DECR2	OSGIN1	psi-mi:“MI:0915”(physical association)	0.560
GORASP1	PPP6R2	psi-mi:“MI:0914”(association)	0.530
DECR2	WDTC1	psi-mi:“MI:0915”(physical association)	0.500
DECR2	EP300	psi-mi:“MI:0915”(physical association)	0.370
Flnb	RPL22	psi-mi:“MI:0914”(association)	0.350
PPP2CB	DKFZP586J0619	psi-mi:“MI:0914”(association)	0.350
LIMA1	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
Coro1c	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
Myh9	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
RNASEH2A	PHF20L1	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
CAPZB	ENAH	psi-mi:“MI:0914”(association)	0.350
GORASP2	PGRMC1	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350
PEX5	AGPS	psi-mi:“MI:0914”(association)	0.350
PDGFRA	GXYLT2	psi-mi:“MI:0914”(association)	0.350
OSTM1	ILVBL	psi-mi:“MI:0914”(association)	0.350
	POLR3A	psi-mi:“MI:0914”(association)	0.350
	POLRMT	psi-mi:“MI:0914”(association)	0.350

BioGRID (67): SESTD1 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), SESTD1 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Affinity Capture-MS), DECR2 (Proximity Label-MS)

ESM2 similar proteins: A0A084B9Z1, A0A0S2CGD3, A0A0U5GHD4, A0A142I726, A0A144Y7G4, A0A162J3X8, A0A1B2CTA9, A0A1L9WLE6, A0A1Y0BRF8, A0A3G9HAL8, A0A411KUU9, A0A443HJZ3, A0A455R5K2, A0A4P8GEE8, A0A8J9S3B0, A3F5F0, B6H061, B8M9K8, F4J300, G0RNA2, G4N1P8, L0E2Z4, L7I518, L7WRR9, M1VVW5, M2Y1A3, M2YJK1, O08756, O94207, P32573, Q08632, Q5AR48, Q5KTS5, Q5RBV3, Q6NV34, Q75KH3, Q7SHI1, Q7SHI4, Q93761, Q94KL8

Diamond homologs: A0A1A9TAK5, A0A1C9II22, A0A7T8F1N2, A0AAW1NHX6, A4UHT7, A7B3K3, A7DY56, B2GV72, B2X050, B8A5W4, C0KTJ6, I1RL15, M2ZIX7, O34308, O74959, O75828, P0AET8, P0AET9, P16152, P35320, P38004, P40471, P42317, P47727, P47844, P48758, P50165, P50205, P76633, Q03326, Q071N0, Q12634, Q28960, Q3SZD7, Q4A054, Q5F389, Q5R9W5, Q5RBV3, Q5RCU5, Q6NV34

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

100 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	68
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2162 predictions. Top by Δscore:

Variant	Effect	Δscore
16:406398:G:GG	donor_gain	1.0000
16:407561:G:GG	donor_gain	1.0000
16:410355:G:GT	donor_gain	1.0000
16:410685:TTGCA:T	acceptor_loss	1.0000
16:410686:TGCAG:T	acceptor_loss	1.0000
16:410687:GCAGG:G	acceptor_loss	1.0000
16:410688:CA:C	acceptor_loss	1.0000
16:410970:A:AG	acceptor_gain	1.0000
16:410971:G:GG	acceptor_gain	1.0000
16:410971:GAC:G	acceptor_gain	1.0000
16:410971:GACGC:G	acceptor_gain	1.0000
16:411074:TGGG:T	donor_loss	1.0000
16:411075:GG:G	donor_gain	1.0000
16:411076:GG:G	donor_gain	1.0000
16:411077:G:GG	donor_gain	1.0000
16:411078:T:G	donor_loss	1.0000
16:411359:A:AG	acceptor_gain	1.0000
16:411359:AGGT:A	acceptor_gain	1.0000
16:411360:G:GG	acceptor_gain	1.0000
16:411360:GGT:G	acceptor_gain	1.0000
16:411360:GGTG:G	acceptor_gain	1.0000
16:402041:GCG:G	donor_gain	0.9900
16:402042:CGGT:C	donor_loss	0.9900
16:402044:G:GG	donor_gain	0.9900
16:402044:GTGA:G	donor_loss	0.9900
16:402045:T:G	donor_loss	0.9900
16:402046:GA:G	donor_loss	0.9900
16:402059:G:T	donor_gain	0.9900
16:405022:GCG:G	donor_gain	0.9900
16:406014:G:GT	donor_gain	0.9900

AlphaMissense

1888 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:406375:G:T	R60M	0.996
16:410257:T:C	F118L	0.996
16:410259:C:A	F118L	0.996
16:410259:C:G	F118L	0.996
16:407559:C:A	N112K	0.995
16:407559:C:G	N112K	0.995
16:410256:C:A	N117K	0.994
16:410256:C:G	N117K	0.994
16:410714:C:A	N162K	0.994
16:410714:C:G	N162K	0.994
16:411001:T:A	W196R	0.993
16:411001:T:C	W196R	0.993
16:411459:A:C	S254R	0.993
16:411461:C:A	S254R	0.993
16:411461:C:G	S254R	0.993
16:411483:G:T	G262W	0.992
16:404997:G:A	G41E	0.991
16:410770:C:A	A181D	0.991
16:410774:G:C	K182N	0.991
16:410774:G:T	K182N	0.991
16:411028:A:C	S205R	0.991
16:411030:C:A	S205R	0.991
16:411030:C:G	S205R	0.991
16:404979:G:A	G35E	0.990
16:410775:G:C	A183P	0.990
16:410974:G:C	A187P	0.990
16:404967:C:A	A31D	0.988
16:410258:T:C	F118S	0.988
16:410778:G:C	A184P	0.988
16:410993:C:A	A193D	0.988

dbSNP variants (sampled 300 via entrez): RS1000052107 (16:404480 T>C), RS1000502172 (16:408974 G>A), RS1000941534 (16:409876 G>A,C), RS1001093788 (16:401832 T>A), RS1001358969 (16:404061 T>G), RS1001768402 (16:403890 T>C), RS1001993657 (16:407677 G>A,T), RS1002041385 (16:412138 G>A), RS1002489611 (16:411862 C>T), RS1002494555 (16:403121 C>G,T), RS1002502169 (16:402761 A>G), RS1002751879 (16:400592 C>T), RS1002864346 (16:406468 A>G), RS1003046018 (16:409540 C>T), RS1003268537 (16:408695 T>A,G)

Disease associations

OMIM: gene MIM:615839 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST005951_12	Body mass index	5.000000e-11
GCST009733_65	Urinary metabolite levels in chronic kidney disease	2.000000e-12
GCST012335_3	Hodgkin’s lymphoma	2.000000e-12

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0005116	urinary metabolite measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066268 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs5841	DECR2, NME4		0.00	0

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, decreases expression	2
Arsenic	increases abundance, affects methylation, affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, decreases expression	2
Valproic Acid	decreases methylation, decreases expression	2
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
tetrahydropalmatine	increases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
aflatoxin B2	increases methylation	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
beta-methylcholine	affects expression	1
avobenzone	decreases expression	1
K 7174	decreases expression	1
nutlin 3	affects cotreatment, increases expression, increases secretion	1
bisphenol B	increases expression	1
jinfukang	affects cotreatment, increases expression	1
MT19c compound	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases expression, increases secretion	1
Dimethyl Sulfoxide	increases expression	1
Gasoline	decreases expression, increases abundance, affects cotreatment	1
Ivermectin	decreases expression	1
Manganese	decreases expression, increases abundance, affects cotreatment	1
Methyl Methanesulfonate	increases expression	1
NADP	affects binding, increases activity	1
Phthalic Acids	increases methylation	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, decreases expression, increases abundance	1
Smoke	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651270	Binding	Binding affinity to human DECR2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.